Insulin therapy and type 2 diabetes: management of weight gain.
The potential for insulin-related weight gain in patients with type 2 diabetes presents a therapeutic dilemma and frequently leads to delays in the initiation of insulin therapy. It also poses considerable challenges when treatment is intensified. Addressing insulin-related weight gain is highly relevant to the prevention of metabolic and cardiovascular consequences in this high-risk population with type 2 diabetes. In addition to lifestyle changes (eg, diet and exercise) and available medical interventions to minimize the risk of weight gain with insulin treatment, familiarity with the weight gain patterns of different insulins may help deal with this problem. The use of basal insulin analogs may offer advantages over conventional human insulin preparations in terms of more physiologic time-action profiles, reduced risk of hypoglycemia, and reduced weight gain.
McFarlane
Samy I
SI
Division of Endocrinology, College of Medicine, State University of New York-Downstate, Brooklyn, NY 11203, USA. samy.mcfarlane@downstate.edu
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D004035:Diet Therapy; D005081:Exercise Therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D007328:Insulin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D009765:Obesity / Q000517:prevention & control / Q000628:therapy; D015430:Weight Gain / Q000187:drug effects* / Q000502:physiology
D007004:Hypoglycemic Agents; D007328:Insulin